Company intelligence / Profile preview

FluidForm Bio

Waltham, Massachusetts, United Statesfluidformbio.com ↗

Ownership: Private
Development stage: Preclinical

Overview

The company has recently published groundbreaking research in Science Advances detailing the development of CHIPS (Collagen-based High-resolution Internally Perfusable Scaffolds), demonstrating the ability to fabricate centimeter-scale tissue constructs with unprecedented precision and functional fidelity. Their technology enables dynamic perfusion, vascularization, and glucose-stimulated insulin secretion in engineered tissue constructs[6].

Therapeutic areas: Endocrinology
Modalities: Cell therapies3D bioprinted tissues
Industry: Biotech

Partnerships

Carnegie Mellon Universitypharmaceutical and biotech companies (specific names not provided)

Beyond the preview

Go deeper on FluidForm Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FluidForm Bio.

Explore the full profile